Cardiovascular Diseases

Helsinn Group grants exclusive licensing rights to Blanver and Varifarma for its leading drug Pracinostat in South America. Helsinn is a Swiss biopharmaceutical company committed to producing the best solutions aimed at improving the quality of life for people with cancer. Under the terms of the agreements, São Paulo-based Blanver will have the rights to register, promote, distribute and commercialize Pracinostat in Brazil, on the other hand Varifarma, located in Buenos Aires, will have the rights for the same but in different geography namely Argentina, Bolivia, Chile, Colombia, Ecuador, Paraguay, Peru, and Uruguay. However, Helsinn will retain all internation...